NGM Biopharmaceuticals, AstraZeneca deal

AstraZeneca's MedImmune LLC biologics unit partnered with NGM to develop and commercialize peptide and antibody therapeutics to treat Type II diabetes and obesity based on a set of undisclosed secret...